Funder: Alzheimers Drug Discovery Foundation
Due Date: December 8, 2017
The true test for new Alzheimer’s drugs is in human clinical trials. Numerous treatments for Alzheimer’s disease have been shown to be safe and to have some positive effect when tested in animal models of Alzheimer’s disease. However, many of these potentially successful treatments have not been brought to human trials because of the increased cost and risk at this stage of research.
The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer’s disease, related dementias, and cognitive aging. This program will fund exploratory Phase 0 microdosing studies that assess preliminary target engagement and PK, Phase I safety testing, Phase 2 biomarker-based proof-of-concept clinical trials in patients, as well as IND-enabling studies to accelerate new drugs into trials. Through this PACT RFP, the ADDF is also interested in supporting biomarker-based trials to validate putative mechanisms of action for targeted pharmacological and non-pharmacological approaches to prevention.
Average Duration: Varies
Average Award: Up to $3 million